Healthcare / Medical DevicesHelsinki
$13.30
+0.46 (+3.41%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $19.7M · quality 76.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$354M
P/E
22.5x
↑EV/EBITDA
12.2x
↓ROE
15.2%
↑Gross Margin
70.9%
↑Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.2%
FCF CAGR
+7.0%
FCF margin
23.8%
FCF / Net income
1.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $109.7M · net income $17.4M · FCF $26.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $109.7M | $109.7M | $103.5M | $96.6M | $97.0M |
| Net Income | $17.4M | $17.4M | $18.5M | $19.1M | $21.8M |
| EBITDA | $27.7M | $27.7M | $30.5M | $30.1M | $32.8M |
| EPS | 0.65 | 0.65 | 0.69 | 0.72 | 0.82 |
| Gross Margin | 70.9% | 70.9% | 70.5% | 70.7% | 71.9% |
| Operating Margin | 23.2% | 23.2% | 24.2% | 27.3% | 30.6% |
| Net Margin | 15.9% | 15.9% | 17.9% | 19.8% | 22.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.10 | 0.10 | 0.12 | 0.18 | 0.22 |
| Current Ratio | 2.27 | 2.27 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $26.1M | $26.1M | $19.7M | $6.8M | $21.2M |
| Returns | |||||
| ROE | 15.2% | 15.2% | 17.2% | 19.1% | 23.9% |
| Valuation | |||||
| P/E | 22.54 | 22.54 | 39.11 | 36.11 | 45.80 |
| EV/EBITDA | 12.22 | 12.22 | 23.45 | 22.84 | 30.06 |
| P/B | 3.08 | 3.08 | 6.71 | 6.91 | 10.96 |
| Growth & Yield | |||||
| Revenue Growth | 6.0% | 6.0% | 7.2% | -0.4% | — |
| EPS Growth | -5.8% | -5.8% | -3.0% | -12.2% | — |
| Dividend Yield | 2.0% | 2.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
21.7%
EPS terminal req.
$1.18
Spread vs growth
-27.5%
5Y implied EPS CAGR
16.9%
EPS terminal req.
$1.43
Spread vs growth
-22.7%
10Y implied EPS CAGR
13.4%
EPS terminal req.
$2.30
Spread vs growth
-19.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-48.4%
Start / end P/E
40.5x → 21.3x
EPS bridge
0.69 → 0.65
Residual
+2.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.